Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5100 - Should pancreatic cancer be included in BRCA1/2 testing criteria?

Date

09 Sep 2017

Session

Poster display session

Presenters

Marta Venturelli

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

M. Venturelli1, A. Toss1, S. Pipitone1, I. Marchi1, E. Tenedini2, V. Medici2, E. Tagliafico2, E. Razzaboni1, F. Spaggiari1, E. De Matteis3, S. Cascinu1, L. Cortesi1

Author affiliations

  • 1 Department Of Oncology And Hematology, University of Modena and Reggio Emilia, 41121 - Modena/IT
  • 2 Center For Genome Research, University of Modena and Reggio Emilia, 41121 - Modena/IT
  • 3 Department Of Oncology And Hematology, Vito Fazzi Hospital, 73100000 - Lecce/IT
More

Resources

Abstract 5100

Background

BRCA1/2 mutation carriers have an increased risk for breast cancer (BC), ovarian cancer (OC), prostate cancer and pancreatic cancer (PC). On this basis, the NCCN Guidelines include prostate and PC among the BRCA testing criteria. In our Institution, BRCA diagnostic test is exclusively offered to patients affected by BC or OC, according to the Modena criteria, or to healthy women with BRCAPro> 40%. The aim of this study was to compare the rate of positive BRCA test in families with PC, classified according to NCCN guidelines or Modena criteria.

Methods

We retrospectively analyzed families with family history of PC registered in the archive of our Family Cancer Clinic. Analysis of BRCA1/2 mutation was evaluated in these families and the BRCA mutation detection rate was calculated according to both selection criteria. We also evaluated age at diagnosis and overall survival of patients affected by PC.

Results

435 families with at least one diagnosis of PC have been identified. 393 families had PC and BC and/or OC cases and were included in our analysis. 55.5% of these families were candidate to BRCA testing according to the Modena Criteria, whereas 90.8% of families were candidate according to the NCCN Guidelines. 65.6% of families selected according with the Modena Criteria underwent BRCA test, identifying 19 BRCA1 mutations and 16 BRCA2 mutations (detection rate 24.5%). 45.9% of families with the NCCN Criteria underwent the test with the identification of the same mutations (detection rate 21.3%). Mean age at PC diagnosis was lower in patients with family history of BC and/or OC (65.8 years) and in BRCA mutated families (65.7 years) than in general population (72 years). One-year OS rate was higher in patients with family history of BC and/or OC (41.3%) and in BRCA mutated families (50%) than in general population (23%). 5-year OS was around 5% for patients with family history or BRCA mutation in the family and general population.

Conclusions

Our retrospective study confirms the high rate of positive BRCA1/2 test in families with PC associated to BC and/or OC. The NCCN Guidelines compared to the Modena Criteria did not increase the BRCA mutation detection rate. Notably, PC diagnosed in families with history of BC and/or OC or BRCA mutation showed younger age at diagnosis and better 1-year OS. We are planning to test all the remaining families selected by NCCN guidelines.

Clinical trial identification

Legal entity responsible for the study

Dr. Laura Cortesi

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.